Nycomed 2nd-qtr 2011 sales flat, but emerging markets up 23.5%
Swiss independent drugmaker Nycomed, which is the subject of an acquisition by Japan’s largest pharma firm Takeda, has posted second-quarter 2011 financials, with year-on-year sales flat at 786.2 million euros ($1.12 billion) but up 2.4% in local currencies.
EBITDA for the quarter was down 4.5% at 188.6 million euros (+2.2% in local currencies); although for the first half of the year EBITDA rose 16.4% to 501.0 million, including a one-time Forest Laboratories payment (+16.5% in local currencies).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze